Physician profile
Jeremy Alexander Sunseri
NPI 1831400100
$81,443.11
in general payments reported to CMS, 2019-2025
15 companies · $43K in 2025
The $43K reported for 2025 was more than what 99% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $525 · 2020: $129 · 2021: $350 · 2022: $653 · 2023: $738 · 2024: $36K · 2025: $43K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $64K · Travel and Lodging: $12K · Food and Beverage: $3,838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $64,274.55 |
| Travel and Lodging | $11,673.04 |
| Food and Beverage | $3,838.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $79,229.44 | 2021-2025 | Affinity, Novachor, Puraply Wound Matrix |
| Galderma Laboratories, L.P. | $1,010.90 | 2019-2025 | Dysport |
| Abbvie INC. | $560.74 | 2019-2025 | Rinvoq |
| Allergan, INC. | $222.07 | 2019-2020 | |
| Lilly USA, LLC | $97.92 | 2021-2025 | Taltz, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $73.03 | 2019-2023 | Dupixent |
| Genzyme Corporation | $63.30 | 2020-2023 | |
| Genentech USA, INC. | $37.00 | 2019-2023 | Erivedge |
| Journey Medical Corporation | $32.09 | 2024 | |
| Solta Medical, A Division of Bausch Health US, LLC | $25.31 | 2025 | |
| Merz North America, INC. | $24.98 | 2020 | |
| Janssen Biotech, INC. | $21.08 | 2024 | Simponi Aria, Tremfya, Stelara |
| Verrica Pharmaceuticals INC. | $18.03 | 2024 | Ycanth |
| Pfizer INC. | $14.72 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $12.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremy Sunseri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.